Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991

被引：0
|
作者：
Sheppard, Karen E. [1 ]
Foo, Allen [1 ]
Young, Richard [1 ]
Waldeck, Kelly [1 ]
Pearson, Richard [1 ]
McArthur, Grant [1 ]
Christensen, James [2 ]
机构：
[1] Peter MacCallum Canc Ctr, East Melbourne, Australia
[2] Pfizer Oncol, Global Res & Dev, San Diego, CA USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-3416
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3416
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cracking the Genomic Code of CDK4/6 Inhibitor Resistance
    Wander, Seth A.
    Bardia, Aditya
    CLINICAL CANCER RESEARCH, 2024, 30 (10) : 2008 - 2010
  • [22] Synergistic anti-cancer activity of the CDK4/6 inhibitor PD-0332991 in combination with 5-fluorouracil-based chemotherapy in human colon cancer cells
    Pishvaian, Michael J.
    Yang, Shaoxian
    El Zouhairi, Majed
    Wu, Christina S.
    Mishra, Lopa
    Avantaggiati, Maria-Laura
    CANCER RESEARCH, 2010, 70
  • [23] Synergistic anti-cancer activity of the CDK4/6 inhibitor PD-0332991 in combination with 5-fluorouracil-based chemotherapy in human colon cancer cells
    Pishvaian, Michael J.
    Yang, Shaoxian
    El Zouhairi, Majed
    Wu, Christina S.
    Mishra, Lopa
    Avantaggiati, Maria-Laura
    CANCER RESEARCH, 2010, 70
  • [24] Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy
    Kong, Yan
    Sheng, Xinan
    Wu, Xiaowen
    Yan, Junya
    Ma, Meng
    Yu, Jiayi
    Si, Lu
    Chi, Zhihong
    Cui, Chuanliang
    Dai, Jie
    Li, Yiqian
    Yu, Huan
    Xu, Tianxiao
    Tang, Huan
    Tang, Bixia
    Mao, Lili
    Lian, Bin
    Wang, Xuan
    Yan, Xieqiao
    Li, Siming
    Guo, Jun
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6946 - 6957
  • [25] The effect of CDK4 inhibitor to AML
    Wang, Jie
    Briesewitz, Roger
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 115 - 115
  • [26] The effect of CDK4 inhibitor to AML
    wang, Jie
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 62 - 62
  • [27] Inducible deletion of CDK4 and CDK6-deciphering CDK4/6 inhibitor effects in the hematopoietic system
    Maurer, Barbara
    Brandstoetter, Tania
    Kollmann, Sebastian
    Sexl, Veronika
    Prchal-Murphy, Michaela
    HAEMATOLOGICA, 2021, 106 (10) : 2624 - 2632
  • [28] Evaluation of genetic melanoma vaccines in cdk4 mutant mice
    Steitz, J
    Lenz, J
    Buechs, S
    Huber, C
    Woelfel, T
    Barbacid, M
    Malumbres, M
    Tueting, T
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A153 - A153
  • [29] PALBOCICLIB Cyclin CDK4/CDK6 Inhibitor Oncolytic
    Haddley, K.
    DRUGS OF THE FUTURE, 2013, 38 (11) : 745 - 755
  • [30] The identification of combinations for the CDK4 and CDK6 inhibitor, abemaciclib
    Gong Xueqian
    Chio, Li-Chun
    Webster, Yue
    Lallena, Maria Jose
    Boehnke, Karsten
    Torres, Raquel
    Iversen, Phil
    De Dios, Alfonso
    Smith, Ian
    Reinhard, Christoph
    Peng, Sheng-Bin
    Dempsey, Jack
    Burke, Teresa
    Chen, Shih-Hsun
    Stewart, Trent
    Beckmann, Richard
    Wu, Wenjuan
    Buchanan, Sean G.
    MOLECULAR CANCER RESEARCH, 2016, 14
12345